ABVC vs. PMN, VYNE, NNVC, MRKR, UNCY, BOLT, ACST, EQ, ENLV, and SPRB
Should you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include ProMIS Neurosciences (PMN), VYNE Therapeutics (VYNE), NanoViricides (NNVC), Marker Therapeutics (MRKR), Unicycive Therapeutics (UNCY), Bolt Biotherapeutics (BOLT), Acasti Pharma (ACST), Equillium (EQ), Enlivex Therapeutics (ENLV), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical preparations" industry.
ProMIS Neurosciences (NASDAQ:PMN) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
ABVC BioPharma has higher revenue and earnings than ProMIS Neurosciences. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.
ProMIS Neurosciences has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.
In the previous week, ABVC BioPharma had 1 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 0.49 beat ABVC BioPharma's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media.
50.1% of ProMIS Neurosciences shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 6.4% of ProMIS Neurosciences shares are owned by insiders. Comparatively, 11.9% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ProMIS Neurosciences presently has a consensus target price of $8.00, indicating a potential upside of 351.98%. Given ABVC BioPharma's higher probable upside, equities research analysts plainly believe ProMIS Neurosciences is more favorable than ABVC BioPharma.
ProMIS Neurosciences has a net margin of 0.00% compared to ProMIS Neurosciences' net margin of -50,504.00%. ProMIS Neurosciences' return on equity of -207.72% beat ABVC BioPharma's return on equity.
ProMIS Neurosciences received 2 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
Summary
ABVC BioPharma beats ProMIS Neurosciences on 9 of the 16 factors compared between the two stocks.
Get ABVC BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABVC BioPharma Competitors List
Related Companies and Tools
